Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.

Autor: Zapata-Cobo P; Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Salvador-Martín S; Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Velasco M; Hospital Universitario Infantil Niño Jesús, Madrid, Spain., Palomino LM; Hospital Universitario Infantil Niño Jesús, Madrid, Spain., Clemente S; Hospital Vall d'Hebrón, Barcelona, Spain., Segarra O; Hospital Vall d'Hebrón, Barcelona, Spain., Moreno-Álvarez A; Hospital Universitario A Coruña, A Coruña, Spain., Fernández-Lorenzo A; Hospital Universitario A Coruña, A Coruña, Spain., Pérez-Moneo B; Hospital Universitario Infanta Leonor, Madrid, Spain., Montraveta M; Hospital Universitario Germans Trias i Pujol, Badalona, Spain., Sánchez C; Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Tolín M; Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Loverdos I; Hospital Universitario Parc Taulí, Sabadell, Spain., Fobelo MJ; Hospital Universitario Virgen de Valme, Universidad de Sevilla, Sevilla, Spain., Navas-López VM; Hospital Regional Universitario de Málaga, Spain., Magallares L; Hospital Universitario la Paz, Madrid, Spain., García-Romero R; Hospital Universitario Miguel Servet, Zaragoza, Spain., Sánchez-Hernández JG; Complejo Asistencial Universitario de Salamanca, Salamanca, Spain., Rodríguez A; Hospital Universitario Virgen del Rocio, Sevilla, Spain., Bossacoma F; Servicio de Gastroenterología, Hepatología y Nutrición Pediátrica, Hospital Sant Joan de Dèu, Barcelona, Spain., Balboa MJ; Hospital Universitario Virgen de la Macarena, Sevilla, Spain., Salcedo E; Hospital Universitario Doce de Octubre, Madrid, Spain., Sanjurjo-Sáez M; Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain., López-Fernández LA; Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Electronic address: Luis.lopez@iisgm.com.
Jazyk: angličtina
Zdroj: Pharmacological research [Pharmacol Res] 2023 Aug; Vol. 194, pp. 106859. Date of Electronic Publication: 2023 Jul 19.
DOI: 10.1016/j.phrs.2023.106859
Abstrakt: Few genetic polymorphisms predict early response to anti-TNF drugs in inflammatory bowel disease (IBD), and even fewer have been identified in the pediatric population. However, it would be of considerable clinical interest to identify and validate genetic biomarkers of long-term response. Therefore, the aim of the study was to analyze the usefulness of biomarkers of response to anti-TNFs in pediatric IBD (pIBD) as long-term biomarkers and to find differences by type of IBD and type of anti-TNF drug. The study population comprised 340 children diagnosed with IBD who were treated with infliximab or adalimumab. Genotyping of 9 selected SNPs for their association with early response and/or immunogenicity to anti-TNFs was performed using real-time PCR. Variants C rs10508884 (CXCL12), A rs2241880 (ATG16L1), and T rs6100556 (PHACTR3) (p value 0.049; p value 0.03; p value 0.031) were associated with worse long-term response to anti-TNFs in pIBD. DNA variants specific to disease type and anti-TNF type were identified in the pediatric population. Genotyping of these genetic variants before initiation of anti-TNFs would enable, if validated in a prospective cohort, the identification of pediatric patients who are long-term responders to this therapy.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE